Expression of CD30 as a biomarker to predict response to brentuximab vedotin

Histopathology

Volumn 69, Issue 1, 2016, Pages 155-158

  Xu, Mina L ^a   Acevedo Gadea, Carlos ^a   Seropian, Stuart ^a   Katz, Samuel G ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRENTUXIMAB VEDOTIN; CD30 LIGAND;

CANCER CELL; CLASSICAL HODGKIN LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; DRUG RESPONSE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; TUMOR VOLUME;

EID: 84974707568     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12914     Document Type: Letter

References (5)

1. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299; 65–67.
2. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 2012; 30; 2183–2189.
3. Bossard C, Dobay MP, Parrens M et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood 2014; 124; 2983–2986.
4. Jacobsen ED, Sharman JP, Oki Y et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015; 125; 1394–1402.
5. Kim YH, Tavallaee M, Sundram U et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable cd30 expression level: a multi-institution collaborative project. J. Clin. Oncol. 2015; 33; 3750–3758.